MA24569A1 - Inhibiteurs de farnesyl-transferase en association avec des inhibiteurs de hmg-coa-reductase pour le traitement du cancer - Google Patents

Inhibiteurs de farnesyl-transferase en association avec des inhibiteurs de hmg-coa-reductase pour le traitement du cancer

Info

Publication number
MA24569A1
MA24569A1 MA25114A MA25114A MA24569A1 MA 24569 A1 MA24569 A1 MA 24569A1 MA 25114 A MA25114 A MA 25114A MA 25114 A MA25114 A MA 25114A MA 24569 A1 MA24569 A1 MA 24569A1
Authority
MA
Morocco
Prior art keywords
inhibitors
farnesyl
hmg
coa
cancer
Prior art date
Application number
MA25114A
Other languages
English (en)
Inventor
Mohamed Kajiji Shama
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA24569A1 publication Critical patent/MA24569A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA25114A 1997-06-16 1998-06-15 Inhibiteurs de farnesyl-transferase en association avec des inhibiteurs de hmg-coa-reductase pour le traitement du cancer MA24569A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4963897P 1997-06-16 1997-06-16

Publications (1)

Publication Number Publication Date
MA24569A1 true MA24569A1 (fr) 1998-12-31

Family

ID=21960890

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25114A MA24569A1 (fr) 1997-06-16 1998-06-15 Inhibiteurs de farnesyl-transferase en association avec des inhibiteurs de hmg-coa-reductase pour le traitement du cancer

Country Status (37)

Country Link
EP (1) EP0986387B1 (fr)
JP (1) JP3713051B2 (fr)
KR (1) KR100392573B1 (fr)
CN (1) CN1259868A (fr)
AP (1) AP9801261A0 (fr)
AR (1) AR013090A1 (fr)
AT (1) ATE235905T1 (fr)
BG (1) BG103946A (fr)
BR (1) BR9810616A (fr)
CA (1) CA2294399C (fr)
CO (1) CO4950607A1 (fr)
DE (1) DE69812933T2 (fr)
DK (1) DK0986387T3 (fr)
DZ (1) DZ2518A1 (fr)
EA (1) EA199901043A1 (fr)
ES (1) ES2196559T3 (fr)
GT (1) GT199800081A (fr)
HN (1) HN1998000091A (fr)
HR (1) HRP980328B1 (fr)
HU (1) HUP0004624A3 (fr)
ID (1) ID23014A (fr)
IL (1) IL132765A0 (fr)
IS (1) IS5259A (fr)
MA (1) MA24569A1 (fr)
NO (1) NO996206L (fr)
NZ (1) NZ500662A (fr)
OA (1) OA11231A (fr)
PA (1) PA8453601A1 (fr)
PE (1) PE82899A1 (fr)
PL (1) PL337651A1 (fr)
PT (1) PT986387E (fr)
SK (1) SK169699A3 (fr)
TN (1) TNSN98088A1 (fr)
TR (1) TR199903074T2 (fr)
UA (1) UA57081C2 (fr)
WO (1) WO1998057633A1 (fr)
ZA (1) ZA985182B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200000660A (et) * 1998-05-12 2002-04-15 Warner-Lambert Company Valk farnesüültransferaasi ja HMG CoA reduktaasi inhibiitorite kombinatsioonid ja nende kasutamine vähi raviks
WO2000016778A1 (fr) * 1998-09-24 2000-03-30 Merck & Co., Inc. Procede de traitement du cancer
EP1006113A1 (fr) * 1998-12-02 2000-06-07 Pfizer Products Inc. Dérivés de 2-(2-oxo-éthylidène)-imidazolidin-4-one et leur utilisation pour inhiber la croissance anormale des cellules
AU4988100A (en) * 1999-05-07 2000-11-21 Brigham And Women's Hospital Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
BR0116302A (pt) 2000-12-19 2004-01-13 Pfizer Prod Inc Formas cristalinas de sais 2,3-dihidroxibutanodioato de 6-[(4-clorofenil)-hidróxi-(3-metil-3h-imidazol-4-il)-meti l]-4-(3-etinil-fenil)-1-metil-1h-quinolin-2-ona e método de produção
CA2432642A1 (fr) 2000-12-21 2002-08-08 Subhash P. Khanapure Composes aryle substitues en tant que nouveaux inhibiteurs selectifs de la cyclo-oxygenase-2, compositions et methodes d'utilisation
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
JP2005200419A (ja) * 2004-01-16 2005-07-28 National Health Research Inst 癌治療法
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0856315B1 (fr) * 1995-08-09 2005-08-24 Banyu Pharmaceutical Co., Ltd. Inhibiteurs de la proteine farnesyltransferase en combinaison avec des inhibiteurs de hmgcoa-reductase pour le traitement de sida

Also Published As

Publication number Publication date
WO1998057633A1 (fr) 1998-12-23
HN1998000091A (es) 1999-09-29
JP2000513031A (ja) 2000-10-03
SK169699A3 (en) 2000-06-12
PE82899A1 (es) 1999-08-26
CA2294399A1 (fr) 1998-12-23
NO996206L (no) 2000-02-15
AU724676B2 (en) 2000-09-28
AR013090A1 (es) 2000-12-13
TNSN98088A1 (fr) 2005-03-15
ES2196559T3 (es) 2003-12-16
DE69812933T2 (de) 2003-11-06
JP3713051B2 (ja) 2005-11-02
DK0986387T3 (da) 2003-07-14
NZ500662A (en) 2001-10-26
AU7445998A (en) 1999-01-04
BG103946A (bg) 2000-07-31
AP9801261A0 (en) 1999-12-11
DE69812933D1 (de) 2003-05-08
HRP980328A2 (en) 1999-04-30
IL132765A0 (en) 2001-03-19
CN1259868A (zh) 2000-07-12
EP0986387A1 (fr) 2000-03-22
HRP980328B1 (en) 2002-06-30
ID23014A (id) 1999-12-30
HUP0004624A3 (en) 2002-11-28
BR9810616A (pt) 2000-09-12
ZA985182B (en) 1999-12-17
IS5259A (is) 1999-11-19
CO4950607A1 (es) 2000-09-01
PT986387E (pt) 2003-06-30
EA199901043A1 (ru) 2000-06-26
EP0986387B1 (fr) 2003-04-02
UA57081C2 (uk) 2003-06-16
PL337651A1 (en) 2000-08-28
KR100392573B1 (ko) 2003-07-23
ATE235905T1 (de) 2003-04-15
NO996206D0 (no) 1999-12-15
KR20010013839A (ko) 2001-02-26
PA8453601A1 (es) 2000-05-24
TR199903074T2 (xx) 2000-05-22
OA11231A (en) 2003-05-26
DZ2518A1 (fr) 2003-02-01
HUP0004624A2 (hu) 2001-10-28
GT199800081A (es) 1999-12-07
CA2294399C (fr) 2004-03-16

Similar Documents

Publication Publication Date Title
FR12C0077I2 (fr) Composition pour le traitement des condylomes génitaux
CY2006007I2 (el) Χρηση αναστολεων cgmp-φωσφοδιεστερασης στην αγωγη της ανικανοτητας
NO986052L (no) Anticonvulsivt virkende sulfamatderivater for anvendelse ved behandling av fedme
DE69624812T2 (de) Verringerung des mehrwegeffekts in gps-empfängern
IL142908A0 (en) Compounds useful in the treatment of inflammatory diseases
DE69838374D1 (de) Prozessor und Verfahren zum Verringern von dessen Energieverbrauch
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
FR08C0013I2 (fr) Utilisation de et743 en thérapie combinée avec dexaméthasone pour traiter le cancer
DE69707471T2 (de) Metalloberflächenbehandlung
MA24569A1 (fr) Inhibiteurs de farnesyl-transferase en association avec des inhibiteurs de hmg-coa-reductase pour le traitement du cancer
MA25234A1 (fr) Vibromasseur pour le soulagement des maux et de la douleur.
ZA964762B (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders.
ZA964761B (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders.
NZ307958A (en) Benzisoxazole and indazole derivatives as long acting antipsychotic agents and particularly in the treatment of schizophrenia
DZ2665A1 (fr) Conjugués utiles pour le traitement du cancer de la prostate.
AU9226198A (en) The use of an nadph-oxidase inhibitor in the treatment of reperfusion injury
GB9816234D0 (en) Compounds for use in the treatment of inflammation
HK1025954A1 (en) Triptolide derivatives useful in the treatment of autoimmune diseases
ZA958558B (en) Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
AU3843600A (en) Bath equipped with water vibrator and therapeutic method using the same
IL141056A0 (en) Protease inhibitors for use in the treatment of psoriasis
HK1043477A1 (zh) 轉相溫度乳液在發酵過程中的應用
DE69713442D1 (de) Thioürazil-Derivate und diese enthaltende Metall-Oberflächebehandlungsmittel
IT1268346B1 (it) Metodo per la fabbricazione di ferri da stiro con soletta in acciaio
FR2751572B1 (fr) Procede pour traiter superficiellement des pieces embouties et pieces obtenues suivant ce procede